^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive + CD20 positive

    i
    Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2, CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    494216; 930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma. (PubMed, Oncoimmunology)
    This approach increases the apparent CD19 antigen density on CD19-positive/CD20-positive lymphoma cells, and prevents antigen-loss induced relapse, as CD19 bound to CD20 remains present on the cell surface. We demonstrate that this novel therapeutic prevents and reverses lymphoma relapse in vitro and prevents CD19-negative lymphoma growth and relapse in vivo.
    Journal • CAR T-Cell Therapy • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD20 positive • CD19 positive • CD19 expression • CD19 positive + CD20 positive